Welcome to our dedicated page for 20/20 Biolabs news (Ticker: AIDX), a resource for investors and traders seeking the latest updates and insights on 20/20 Biolabs stock.
20/20 BioLabs news covers the commercialization of its OneTest laboratory blood-test families, including OneTest for Cancer and OneTest for Longevity. Recurring developments include cancer screening programs, practitioner-channel distribution, AI-enabled chronic disease risk assessment, biomarker technology updates, and laboratory operations tied to its CAP-accredited and CLIA-licensed facility.
Company updates also report financial results, Nasdaq public-company milestones, material license or collaboration agreements, and customer-market activity in public-sector, occupational health, functional medicine, and direct-to-consumer channels.
20/20 BioLabs (Nasdaq: AIDX) rescheduled its investor webinar on its OneTest™ multi-cancer early detection business to 2:00 p.m. Eastern time on Wednesday, September 2, 2026, from the previously planned 12:00 p.m. slot.
CEO Jonathan Cohen will review second quarter 2026 results, including record OneTest™ revenue of $0.7 million, up 47.1% year-over-year, and discuss gross profit growth of 86.6% with gross margin expanding to 41.7% from 30.5%. Management plans to cover evolution of the OneTest platform across three generations, state-funded firefighter cancer screening programs in Vermont and Maryland, commercial expansion including 29 new accounts, and regulatory and reimbursement strategy.
The session, part of a monthly investor webinar series, will include live Q&A, a replay on the investor relations site, and a promotional OneTest discount code for attendees. The company does not expect to disclose material non-public information.
20/20 BioLabs (Nasdaq:AIDX) will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. Eastern time to review second quarter 2026 performance and commercial strategy for its OneTest™ multi-cancer early detection platform. CEO Jonathan Cohen will discuss record OneTest™ revenue of $0.7 million, up 47.1% year-over-year, and related gross profit growth of 86.6% with gross margin expanding to 41.7% from 30.5%. Planned topics include evolution of the OneTest™ biomarker platform, firefighter cancer screening programs and expected 2026 revenue from these initiatives, commercial expansion into new channels, the regulatory and reimbursement pathway toward 2028 Medicare coverage for FDA‑authorized MCED blood tests, and a live Q&A. Registration is open to investors and other interested parties.
20/20 BioLabs (Nasdaq: AIDX) reported Q2 2026 revenue of $0.7 million, up 36.5% year over year, with OneTest™ cancer and longevity tests contributing 95.3% of sales and growing 47.1% to $0.7 million. Gross profit rose 86.6% to $0.3 million, expanding gross margin to 41.7% from 30.5% on improved lab utilization.
The company highlighted expanding firefighter, occupational health, military and physician markets, including Vermont and Maryland firefighter screening programs expected to generate more than $1.0 million of revenue and support a target of over 35,000 firefighters tested by year-end 2026. Cash and equivalents increased to $4.5 million from $1.0 million at year-end 2025, aided by $6.0 million of Series E preferred stock proceeds and the exchange of all secured convertible notes into Series E shares, eliminating convertible note debt. Q2 net loss was $1.5 million, and first-half 2026 revenue was flat at $1.1 million versus the prior year while operating expenses rose due to Nasdaq listing and product development costs.
20/20 BioLabs (Nasdaq:AIDX) will host an investor webinar on Wednesday, August 5, 2026, at 12:00 p.m. Eastern time to discuss commercial opportunities following management’s recent East Asia business development tour, including BIO Asia-Taiwan and meetings in Taipei, Tokyo, and Seoul.
According to the company, CEO Jonathan Cohen will outline its East Asia roll-up strategy across potential mergers, acquisitions, licensing, joint ventures, and commercial partnerships, and discuss commercialization plans for OneTest for Cancer, OneTest for Longevity, and CLIAx. Topics are expected to include why East Asia is viewed as a key market for protein biomarker-based cancer screening and longitudinal testing, how regional relationships may support its technology platform and data resources, and its goal of achieving Medicare reimbursement for multi-cancer early detection by the end of 2028. The webinar is part of a monthly series, will feature a live Q&A, a replay on the investor relations site, and a promotional discount code for OneTest for all attendees. The company cautions there is no assurance that East Asia meetings will lead to definitive transactions.
20/20 BioLabs (Nasdaq: AIDX) reported that its management team participated in BIO Asia-Taiwan from July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul as part of its East Asia roll-up strategy. The company is evaluating potential merger, acquisition, licensing, joint venture, and commercial partnership opportunities with regional firms whose products, data assets, laboratories, or technology may complement its AI-powered blood tests for early detection and prevention of cancers and chronic diseases.
20/20 BioLabs is targeting businesses with recurring health-check and diagnostics customers, longevity and prevention offerings, commercial infrastructure for products such as OneTest™ for Cancer and OneTest™ for Longevity, and technology or IP that could enhance its AI testing and evidence-generation strategy. Any potential transactions remain subject to due diligence, negotiations, approvals, and regulatory considerations, with no assurance of completion.
20/20 BioLabs (Nasdaq: AIDX) entered a standstill agreement with Streeterville Capital effective July 16, 2026, covering its outstanding Series E Convertible Preferred Stock. For 120 days, Streeterville will not convert preferred shares to common stock unless AIDX trades at least 10% above the Nasdaq “Minimum Price.”
The arrangement is designed to temporarily limit potential dilution from preferred conversions while keeping all existing rights and obligations under the Series E Preferred Stock and related transaction documents otherwise unchanged. After the standstill ends or is terminated, conversions may resume under existing terms.
20/20 BioLabs (Nasdaq:AIDX) highlighted its July 1, 2026 investor webinar, focusing on OneTest™ multi-cancer early detection, Medicare reimbursement strategy, and revenue trends.
The company expects Q2 2026 MCED revenue to be its highest to date and at least 30% above Q2 2025, based on preliminary unaudited data.
Management outlined evidence-generation plans, including real-world data from an expected 35,000 U.S. firefighters tested by end of 2026, and discussed its Longevity platform and M&A focus. Medicare coverage will require future FDA authorization and CMS determinations, which are not yet obtained and are not assured.
20/20 BioLabs (Nasdaq:AIDX) launched a monthly investor webinar series to update shareholders and investors on company developments. The inaugural session will be held on Wednesday, July 1, 2026, at 12:00 p.m. ET.
Webinars will occur on the first Wednesday of each month, last about 45 minutes, and include direct access to management, plus a promotional OneTest discount code for attendees. Replays will be available on the investor relations website.
20/20 Biolabs (Nasdaq:AIDX) announced that its OneTest™ multi-cancer early detection blood test was selected for a Vermont statewide firefighter cancer screening program, covering up to 4,500 firefighters.
The 12‑month initiative is expected to generate about $500,000 in revenues, with options for two additional years.
According to 20/20 Biolabs, Vermont is the second state funding OneTest™, alongside Maryland, where over $500,000 of tests are expected this quarter, just over $400,000 reimbursed by the Maryland Department of Health. Prior year state-funded revenues were about $105,000. A recent federal law enables a Medicare coverage pathway for MCED tests starting in 2028.
20/20 Biolabs (Nasdaq:AIDX) announced contingency planning to add Ebola and Hantavirus PCR testing in its CAP-accredited CLIA lab if public health labs face overflow demand. The company will leverage prior COVID-19 testing experience, when it processed over 400,000 samples during 2021–2022.
The company is assessing global PCR kit suppliers and repurposing existing equipment to expedite assay validation if needed. The announcement does not indicate current regulatory authorization, clinical availability, or a decision to commercialize these tests.